Hemolytic Uremic Syndrome Medical Services in China

Hemolytic Uremic Syndrome (HUS) is a rare, life-threatening thrombotic microangiopathy characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. It primarily affects the microvasculature—especially in the kidneys—leading to endothelial damage, platelet activation, and fibrin deposition in small arterioles and capillaries. Pathogenesis varies by subtype: Shiga toxin–producing Escherichia coli (STEC-HUS), most commonly linked to E. coli O157:H7 infection following ingestion of undercooked beef or contaminated produce, triggers endothelial injury via ribosomal inactivation and proinflammatory cytokine release. Atypical HUS (aHUS), accounting for ~5–10% of cases, is driven by uncontrolled complement system activation due to genetic mutations (e.g., in CFH, CFI, MCP, C3, or THBD) or autoantibodies against complement regulatory proteins. A third category—secondary HUS—may arise from infections (e.g., pneumococcus), malignancies, autoimmune disorders (e.g., SLE), pregnancy, or certain medications (e.g., calcineurin inhibitors, chemotherapy). Epidemiologically, STEC-HUS peaks in children under 5 years, with an incidence of ~2–3 cases per 100,000 children annually in high-income countries; aHUS has an estimated incidence of 0.2–0.3 per million per year and affects all ages, with median onset in adulthood. Risk factors include young age (for STEC-HUS), inherited complement dysregulation (for aHUS), immunosuppression, recent gastrointestinal illness, and underlying conditions such as hypertension or chronic kidney disease. HUS imposes profound quality-of-life impacts: acute phase symptoms—including pallor, fatigue, oliguria/anuria, edema, seizures, and altered mental status—can necessitate ICU admission, dialysis, and prolonged hospitalization. Survivors often face long-term sequelae: 25–50% develop chronic kidney disease, 3–5% progress to end-stage renal disease requiring transplantation, and neurocognitive deficits, hypertension, and cardiovascular complications may persist. Psychosocial burden includes anxiety, depression, school or work disruption, caregiver strain, and financial hardship—particularly where access to plasma exchange, eculizumab, or specialized nephrology-hematology care is limited. Early recognition and multidisciplinary management involving hematologists, nephrologists, intensivists, and pediatric specialists are critical to mitigating morbidity and mortality.

Hemolytic Uremic Syndrome (HUS) is a life-threatening thrombotic microangiopathy characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. It most commonly arises from Shiga toxin–producing Escherichia coli (STEC) infection—particularly serotype O157:H7—in children, though atypical HUS (aHUS), driven by dysregulation of the alternative complement pathway, accounts for a significant proportion of cases in adults and is often recurrent or familial. Management requires prompt recognition, multidisciplinary coordination, and risk-stratified intervention. Treatment strategies are broadly categorized into conservative, pharmacologic, and surgical modalities, with outcomes heavily dependent on early diagnosis and organ support.

Conservative treatment forms the cornerstone of initial management, especially in STEC-HUS. Fluid resuscitation must be judicious: while early isotonic crystalloid infusion helps maintain renal perfusion and mitigate ischemic tubular injury, excessive volume expansion risks pulmonary edema and hypertension, particularly in patients with evolving oliguric acute kidney injury. Strict electrolyte monitoring—including potassium, sodium, calcium, and phosphate—is essential; hyperkalemia may necessitate emergent interventions such as intravenous calcium gluconate, insulin-dextrose, or sodium bicarbonate. Nutritional support should prioritize low-protein, low-sodium, and low-potassium diets during active renal impairment, transitioning gradually as renal function recovers. Blood pressure control is critical; ACE inhibitors or ARBs are generally avoided acutely due to risk of worsening renal perfusion but may be reintroduced cautiously during recovery if proteinuria persists. Close neurologic surveillance is mandatory, given the risk of seizures, stroke, or encephalopathy secondary to hypertension, uremia, or microvascular cerebral injury.

Pharmacologic therapy differs markedly between STEC-HUS and aHUS. In STEC-HUS, antibiotics and antimotility agents are contraindicated, as they may increase Shiga toxin release and worsen outcomes. Plasma exchange (PEX) has limited evidence in typical HUS and is not routinely recommended unless there is overlapping clinical suspicion of thrombotic thrombocytopenic purpura (TTP) or severe neurologic involvement. In contrast, aHUS mandates targeted complement inhibition. Eculizumab—a humanized monoclonal antibody that binds C5 and prevents terminal complement complex formation—is the first-line therapy. Initiated intravenously (900 mg weekly for four weeks, then 1200 mg every two weeks), it rapidly halts microvascular thrombosis, improves platelet counts, and promotes renal recovery. Ravulizumab, a longer-half-life C5 inhibitor, offers equivalent efficacy with extended dosing intervals (every 8 weeks after loading), enhancing outpatient adherence. For patients with anti-CFH autoantibodies, rituximab may be added to suppress autoantibody production. Corticosteroids have no proven benefit in isolated aHUS and are discouraged outside specific autoimmune contexts. Anticoagulation is not indicated, as HUS is not a primary coagulopathy; heparin or warfarin increases bleeding risk without improving microvascular outcomes.

Surgical treatment plays a highly selective role. Kidney biopsy is rarely performed due to bleeding risk in thrombocytopenic patients and is reserved only when diagnosis remains uncertain despite comprehensive serologic, genetic, and functional testing. Dialysis—either intermittent hemodialysis or continuous renal replacement therapy (CRRT)—is required in approximately 50–70% of pediatric STEC-HUS and up to 90% of aHUS cases with severe AKI. CRRT is preferred in hemodynamically unstable or critically ill patients, including those with encephalopathy or multiorgan failure. Surgical nephrectomy is obsolete and contraindicated. In rare refractory aHUS cases with end-stage kidney disease and persistent complement activation, combined liver-kidney transplantation may be considered—primarily for patients with biallelic CFH or CFI mutations where the liver produces defective complement regulators—but carries substantial perioperative morbidity and requires lifelong immunosuppression and continued complement blockade.

China offers distinct advantages in HUS management, particularly through its integrated national rare disease registry and standardized diagnostic pathways endorsed by the National Health Commission. Major academic centers—including Peking University First Hospital, Shanghai Children’s Medical Center, and West China Hospital—maintain high-volume HUS registries with longitudinal genomic and phenotypic data, facilitating rapid differential diagnosis via next-generation sequencing panels covering >20 complement-related genes (CFH, CFI, CD46, THBD, C3, etc.). Eculizumab was approved in China in 2020 and is now accessible under the National Reimbursement Drug List (NRDL), significantly reducing out-of-pocket costs. Moreover, China’s centralized plasma exchange networks and CRRT-capable ICUs in tier-3 hospitals ensure timely organ support across urban and semi-urban regions. Telemedicine platforms enable real-time consultation between provincial hematologists and national experts, minimizing diagnostic delays. Importantly, Chinese guidelines emphasize early pediatric referral and discourage inappropriate antibiotic use in diarrheal illness—contributing to lower mortality rates (<3% in STEC-HUS at leading centers versus global averages of 5–10%).

Recovery advice must be individualized and longitudinal. Patients recovering from STEC-HUS require serial monitoring of renal function (eGFR, urinalysis, albumin-to-creatinine ratio), blood pressure, and hematologic parameters for at least 12 months; late-onset hypertension and proteinuria may emerge years later. Those with aHUS need indefinite follow-up, including serum C3, C4, CH50, and soluble C5b-9 levels, with eculizumab continuation guided by biomarker trends and clinical stability. Vaccination against encapsulated organisms (e.g., pneumococcus, meningococcus, Haemophilus influenzae type B) is mandatory prior to complement inhibition due to overwhelming post-splenectomy–like infection risk. Patients should avoid NSAIDs, which impair renal perfusion, and receive genetic counseling if pathogenic variants are identified. Psychosocial support—including school reintegration planning for children and vocational counseling for adults—is integral. Long-term renal prognosis varies: ~70% of STEC-HUS survivors regain full renal function, whereas ~50% of aHUS patients progress to chronic kidney disease stage 3 or higher without sustained complement blockade. With modern therapeutics, 5-year patient survival exceeds 95% in specialized centers, underscoring the importance of timely referral to hematologic and nephrologic expertise.